Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes.
TCR mimic
covalent inhibitor
drug discovery
immune therapy
protein engineering
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
ppublish
Résumé
The HapImmune
Identifiants
pubmed: 38781214
doi: 10.1073/pnas.2319029121
doi:
Substances chimiques
Peptides
0
HLA Antigens
0
Haptens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2319029121Subventions
Organisme : HHS | National Institutes of Health (NIH)
ID : R21CA246457
Organisme : HHS | National Institutes of Health (NIH)
ID : R21CA267362
Organisme : HHS | National Institutes of Health (NIH)
ID : R01CA248896
Déclaration de conflit d'intérêts
Competing interests statement:L.M. started his employment at Aethon Therapeutics after the completion of this study. B.G.N. and S.K. hold equity in Aethon Therapeutics that commercializes the technologies described in this paper. HapImmune